Ubrogepant (MK-1602)

Study title/design: Observational study to assess adverse events when adult female participants are treated with ubrogepant or atogepant during pregnancy (EMPRESS, NCT05158894) Trial NCT05827887. Recruiting. Estimated primary completion September 2034, estimated study completion September 2034 Aim To evaluate foetal, maternal, and infant outcomes through 12 months of age among women exposed to ubrogepant or atogepant …

Study title/design: An observational study to assess ubrogepant tablets and atogepant tablets to treat migraine in adult participants (COBRA, NCT05827887) Trial NCT05827887. Recruiting. Estimated primary completion September 2025, estimated study completion September 2025 Aim To evaluate the effectiveness of ubrogepant and atogepant in treating adults with migraine. Study design Participants will receive ubrogepant or atogepant tablets as …

Study title/design: Study of oral ubrogepant to assess adverse events and change in disease activity in adult participants with menstrual migraine (UBRO MM, NCT06417775) Trial NCT06417775. Recruiting. Estimated primary completion June 2027, estimated study completion September 2027 Aim To evaluate the efficacy, safety, and tolerability of ubrogepant for the preventive treatment of menstrual migraine (MM). Study design …

Study title/design: Phase 4 study to assess adverse events when ubrogepant tablets are used in combination with atogepant tablets to treat adult participants with migraine (TANDEM, NCT05264129) Trial NCT05264129 (Completed) Aim Multicentre, open-label study to evaluate the safety, tolerability, and efficacy of concomitant ubrogepant for acute treatment of migraine in patients taking atogepant for the …

Study title/design: A Phase 3 trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral ubrogepant in the acute treatment of migraine with or without aura in children and adolescents (ages 6-17) (Ubro Peds, NCT05125302) Trial NCT05125302. Recruiting. Primary completion 5 May 2026, study completion 5 May 2026. Aim To assess adverse events and …

Study title/design: A randomized, parallel-group, single-attack, open-label study to evaluate the efficacy of almotriptan and ubrogepant for the acute treatment of migraine (ATOM, NCT05214001) Trial NCT05214001. Terminated due to recruitment issues Aim To evaluate the efficacy of almotriptan and ubrogepant for the acute treatment of migraine. Study design A non-inferiority study of almotriptan 12.5 mg …

Study title/design: A prospective observational diary study to evaluate the real-world effectiveness of acute treatment of migraine with ubrogepant when used in combination with atogepant for prevention (COURAGE II, NCT057653986) Trial NCT05653986 Aim To assess change in disease activity when ubrogepant tablets are combined with atogepant tablets to treat migraine in adult participants. Study design …

Study title/design: Ubrogepant efficacy and safety in the treatment of acute migraine in patients currently treated with CGRP monoclonal antibodies (UNION, NCT05503082) Trial NCT05503082. Active, not recruiting. Primary completion September 2024, study completion November 2024. Aim To evaluate the safety and efficacy of ubrogepant in patients currently treated with one of the injectable monoclonal antibodies …

Study title/design: Oral ubrogepant in the acute treatment of migraine when administered during the prodrome (PRODROME) (NCT04492020) Trial NCT04492020 Aim To evaluate the efficacy, safety and tolerability of oral ubrogepant 100 mg in the acute treatment of migraine when administered during the prodrome Study design Adults aged 18-75 years randomised to ubrogepant 100 mg or …

Study title/design: A Phase 1b, two-part, open-label, fixed-sequence, safety, tolerability and drug-drug interaction study between single dose erenumab or galcanezumab and multiple dose ubrogepant in participants with migraine (NCT04179474) Trial NCT04179474 Aim To evaluate the potential of a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab …

Ubrogepant (MK-1602) Study title/design: A Phase 1 multicentre, double-blind, parallel-group trial of intermittent, high-frequency ubrogepant dosing in healthy adults Trial n/a Aim To evaluate the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosing to healthy participants. Study design Healthy adults (age 18-50 years) were randomised 1:1 to placebo or ubrogepant. …

Ubrogepant (MK-1602) Study title/design: A Phase 3 multicenter, randomized, open-label extension study to evaluate the long-term safety and tolerability of oral ubrogepant in the acute treatment of migraine with or without aura Trial NCT02873221 Aim To evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year. …

Ubrogepant (MK-1602) Study title/design: A Phase 3, multicentre, randomised, double-blind, placebo controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE I) Trial NCT02828020 Aim To evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for …

Ubrogepant (MK-1602) Study title/design: A Phase 2 dose-finding study of MK-1602 in the treatment of acute migraine (MK-1602-006) Trial NCT01613248: https://clinicaltrials.gov/ct2/show/NCT01613248 Aim To assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine. Study design Ubrogepant 1, 10, 25, 50 and 100 mg single …

Ubrogepant (MK-1602) Study title/design: A Phase 3, multicentre, randomised, double-blind, placebo controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE II) Trial NCT02867709 Aim To evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for …